)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Hansa Biopharma
Hansa Biopharma (HNSA) investor relations material
Hansa Biopharma Jefferies Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies Global Healthcare Conference 2026 summary4 Jun, 2026
Company overview and platform
Developed a novel IgG degrader platform targeting rapid reduction of IgG for highly sensitized kidney transplant and gene therapy patients.
Pipeline includes a second enzyme targeting Guillain-Barré syndrome.
Market opportunity and unmet need
Around 100,000 patients are on the U.S. kidney wait list, with 15% highly sensitized and facing low chances of finding a match.
Estimated market opportunity for imlifidase exceeds $1 billion due to lack of approved alternatives.
Clinical data and regulatory milestones
Positive phase III top-line data; detailed results to be presented at ATC, including secondary endpoints and safety.
BLA submitted; PDUFA date set for December 19th, with a typical FDA review process underway.
Post-marketing commitments and label scope to be discussed later in the year.
U.S. label expansion strategy for cPRA scores
Hospital economic impact of NTAP and outliers
Strategic rationale for SERB deal structure
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hansa Biopharma
- EU-approved Idefirix and a robust pipeline position the company for global growth in rare disease therapies.HNSA
Ökonomisk Ugebrev presentation12 Jun 2026 - Imlifidase enabled 90% one-year graft failure-free survival in high-risk kidney transplant patients.HNSAStudy result1 Jun 2026
- €115M IDEFIRIX out-licensing boosts cash, secures EU/MENA rights, and funds US launch.HNSAInvestor update22 May 2026
- Imlifidase shows strong results in kidney transplants; European rights sold to fund U.S. launch.HNSAH.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026
- Q1 2026 revenue fell 48%, but cash runway and regulatory milestones were significantly advanced.HNSAQ1 20265 May 2026
- Rapid IgG-cleaving enzyme platform drives growth in transplantation, gene therapy, and autoimmune disease.HNSACorporate presentation23 Apr 2026
- Rapid IgG-cleaving platform drives growth in transplantation, gene therapy, and rare diseases.HNSACorporate presentation16 Mar 2026
- Imlifidase shows strong clinical results, regulatory momentum, and broad expansion potential.HNSALeerink Global Healthcare Conference 20269 Mar 2026
- Imlifidase enables transplantation and gene therapy, backed by strong clinical and financial momentum.HNSARedburn Gene Therapy Summit presentation12 Feb 2026
Next Hansa Biopharma earnings date
CMD 202625 Jun, 2026
Hansa Biopharma
Next Hansa Biopharma earnings date
CMD 202625 Jun, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage